Dave Duffield built PeopleSoft and Workday. His third act, Ridgeline, just raised $250M at a $1.425B valuation to replace the six-to-nine legacy systems running the back office of asset managers with one AI-native platform.
D-Robotics closed a $400M Series C — the day's biggest raise — selling the chips and software inside 20+ rival robot makers, with 8M+ Sunrise chips already shipped.
Open Cosmos raised a €300M Series C — about $348M — to reach unicorn status and give Europe its own sovereign satellite infrastructure, one satellite a day.
A $115B fintech giant got breached without a line of malware: an attacker spoofed a real government email domain, and Revolut mailed back passports, selfies, IBANs, and full Bitcoin transaction histories.
Ivonescimab lived a median 30.8 months vs Keytruda's 22.6 in a head-to-head lung cancer trial — the first clear survival win over the world's best-selling drug.
DeepSeek went out for about $7 billion and investors came back with at least $12 billion, in a Tencent- and CATL-led round ahead of a planned 2027 IPO.
🔥 Gigabyte Just Dropped a $400 WOLED Gaming Monitor and It Changes Everything...
The AI chip company Cerebras Systems — the most prominent challenger to Nvidia's GPU empire — hit the Nasdaq on Thursday under the ticker CBRS and...
> In 2025, startups discovered AI. In 2026, the winners figured out which tools to use and when. Here's the stack the smartest founders are runni...
Bending Spoons is buying Airtable for $1.285 billion in all cash — about 89% below the productivity startup's $11.7B pandemic-era peak, and its first deal since going public.
The FDA just approved FAYUVI, the first-ever treatment for Sanfilippo syndrome type A: a one-time gene therapy from Ultragenyx priced at $3.95 million per patient.
Adicet's off-the-shelf CAR-T put 54% of a small lupus trial into remission on a single dose. Then the stock dropped 22%.
Precision Neuroscience closed an oversubscribed $250M Series D at a ~$1B valuation, betting its surface brain implant beats drilling into tissue.
